文献速递炎症性肠病

急性重度溃疡性结肠炎对静脉激素应答者的长期结局

Long-term outcome of patients with acute severe ulcerative colitis responding to intravenous steroids.
PubMed 文献 · Aliment Pharmacol Ther · 2020-04-28

多中心回顾性研究纳入142例对静脉激素应答的急性重度溃疡性结肠炎患者,中位随访4.8年,63.4%复发,8.5%需结肠切除;1、2、5年无复发生存率分别为58%、48%、40%,早期应答和抗TNF维持治疗与较低复发率相关。

要点

  • 对静脉激素应答的ASUC患者5年无结肠切除生存率约91%,但复发率高达63.4%。
  • 第3天排便<6次/天、第5天部分Mayo评分<2分与较低复发风险独立相关。
  • 抗TNF药物维持治疗与较低复发率独立相关。

核心结论

  • 对静脉激素应答的急性重度溃疡性结肠炎患者虽复发率高,但5年结肠切除率低。
  • 早期对静脉激素应答和生物制剂维持治疗与较低复发率相关。

研究设计与样本

  • 多中心回顾性研究,纳入2006年1月至2017年12月142例对静脉激素应答的急性重度溃疡性结肠炎患者。
  • 应答依据改良Truelove-and-Witts标准判断。

主要发现

  • 142例患者中100例为免疫调节剂和/或生物制剂初治。
  • 出院时59例(41.5%)用5-氨基水杨酸,60例(42%)用免疫调节剂,18例(13%)用抗TNF药物,5例(3.5%)用维得利珠单抗。
  • 中位随访4.8(2.6-7.3)年,90例(63.4%)复发,12例(8.5%)需结肠切除。
  • 1、2、5年无复发生存概率分别为58%、48%、40%;无结肠切除生存概率分别为96%、95%、91%。
  • 多因素分析显示第3天排便<6次/天(HR 0.56,95%CI 0.34-0.91)、第5天部分Mayo评分<2分(HR 0.41,95%CI 0.21-0.80)和抗TNF维持治疗(HR 0.37,95%CI 0.16-0.87)与较低复发风险相关。

关键数值与推荐

  • 复发定义为部分Mayo评分>4分和/或需更换另一种维持治疗。
  • 急性重度溃疡性结肠炎诊断依据改良Truelove-and-Witts标准。

临床怎么用

  • 对静脉激素应答的ASUC患者应重视早期应答评估(第3天排便次数、第5天部分Mayo评分)以识别复发高危者。
  • 抗TNF维持治疗可作为降低复发风险的策略之一。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The long-term outcome of patients with acute severe ulcerative colitis (ASUC) responding to intravenous steroids (IVS) has been poorly reported. AIMS: To assess relapse-free survival in patients with ASUC responding to IVS. METHODS: Between January 2006 and December 2017, 142 consecutive patients with ASUC (according to modified Truelove-and-Witts criteria) responding to IVS were included in this multicentre retrospective study. Relapse was defined by a partial Mayo Clinic score >4 and/or the need for another maintenance therapy. RESULTS: Among the 142 included patients (100 naïve of immunomodulator and/or biological agent) hospitalised for ASUC, 59 (41.5%) were treated at discharge with 5-aminosalicylic acid, 60 (42%) with immunomodulators, 18 (13%) with anti-tumour necrosis factor (TNF) agents and 5 (3.5%) with vedolizumab. After a median follow-up of 4.8 (2.6-7.3) years, 90 (63.4%) had relapsed and 12 (8.5%) had required colectomy. The probabilities of relapse-free survival were 58%, 48% and 40% at 1, 2 and 5 years respectively. The multivariate analysis demonstrated that patients with <6 liquid stools per day at day 3 (hazard ratio 0.56, 95%CI [0.34-0.91]), a partial Mayo Clinic score <2 at day 5 (0.41 [0.21-0.80]) and anti-TNF maintenance therapy (0.37 [0.16-0.87]) were less likely to relapse. The probabilities of colectomy-free survival were 96%, 95% and 91% at 1, 2 and 5 years respectively. CONCLUSION: Despite a high relapse rate, patients with ASUC responding to IVS had a low rate of colectomy after 5 years of follow-up. Early response to IVS and maintenance therapy with biological agents were associated with a lower rate of relapse.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Salameh R, Kirchgesner J, Allez M, et al. Long-term outcome of patients with acute severe ulcerative colitis responding to intravenous steroids. Aliment Pharmacol Ther. 2020. PMID: 32342994. doi:10.1111/apt.15751

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。